Peripheral insulin-like growth factor 1 in bipolar disorder

Area of Science:

• Neuroscience
• Endocrinology
• Psychiatry

Background:

• Bipolar disorder is a debilitating, recurrent mental illness.
• Inflammation and altered insulin-like growth factor 1 (IGF-1) are implicated in bipolar disorder.
• The role of IGF-1 in bipolar disorder pathophysiology requires further investigation.

Purpose of the Study:

• To evaluate serum IGF-1 levels in individuals with bipolar disorder.
• To explore the relationship between serum IGF-1 and inflammation markers in bipolar disorder.
• To compare IGF-1, growth hormone (GH), insulin, and tumor necrosis factor α (TNF-α) levels between patients and controls.

Main Methods:

• Serum concentrations of IGF-1, GH, insulin, and TNF-α were measured.
• 31 patients diagnosed with bipolar disorder were compared to 33 healthy controls.
• Statistical analysis was performed to compare biomarker levels between groups.

Main Results:

• Serum IGF-1 levels were significantly higher in bipolar disorder patients (248.84±104.91 ng/mL) compared to healthy controls (169.18±74.16 ng/mL).
• 32% of bipolar disorder patients exhibited elevated IGF-1 levels, versus 3% in the control group.
• No statistically significant differences were observed in serum concentrations of insulin, GH, or TNF-α between the groups.

Conclusions:

• Elevated peripheral IGF-1 levels are associated with bipolar disorder.
• This increase may be linked to central nervous system resistance to IGF-1, potentially impairing its neuroprotective effects.
• Further research is warranted to elucidate the precise role of IGF-1 in bipolar disorder pathogenesis.